Director/PDMR Shareholding

Feedback

23/12/2025 15:33

RNS Number : 7148M

Feedback PLC

23 December 2025

 

 

Feedback Plc

 

Director/PDMR shareholding

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces that on 23 December 2025 the Company was notified of the following Director and PDMR dealing(s) in the Company's ordinary shares of 1 penny each ("Ordinary Shares"):

 

Tom Oakley, CEO, purchased 60,904 Ordinary Shares at a price of 8.19 pence per Ordinary Share.

 

Emma Oswick (Stuart), (Non-Board) CFO, purchased 60,459 Ordinary Shares at a price of 8.27 pence per Ordinary Share.

 

Details of the Ordinary Shares held are detailed in the table below:

 

Director/ PDMR
Position
Existing interest in Ordinary Shares
Ordinary Shares purchased
Total beneficial interest in Ordinary Shares
Total interest in Company's issued share capital
Tom Oakley
CEO
50,000
60,904
110,904
0.25%
Emma Oswick (Stuart)
(Non-Board) CFO
-
60,459
60,459
0.14%

 

 

The notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation:

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Names
a) Tom Oakley
b) Emma Oswick (Stuart)
2
Reason for the notification
a)
Position/status
a) CEO
b) (Non-Board) CFO
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Feedback plc
b)
LEI
213800UGOF2GT2U2RV90
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares of 1 penny each in Feedback plc
Identification code
GB00BJN59X09
b)
Nature of the transaction
Purchase of Ordinary Shares
Purchase of Ordinary Shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
a) 8.19
a) 60,904
b) 8.27
b) 60,459
d)
Aggregated information
- Aggregated volume
a) £4,988.04
b) £4,999.96
- Price
e)
Date of the transaction
a) 23 December 2025
b) 23 December 2025
f)
Place of the transaction
London Stock Exchange, AIM Market (XLON)

 

 

 

--Ends--

Enquiries:

 

Feedback plc
Tom Oakley, CEO
Emma Oswick, CFO
+44 (0) 20 3997 7634
IR@fbk.com
Panmure Liberum Limited (NOMAD and Broker)
Emma Earl/Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)
+44 (0)20 7886 2500
Walbrook PR Ltd;
Tel: 020 7933 8780 orfeedbackplc@walbrookpr.com
Nick Rome/Joe Walker
07748 325 236 or 07407 020 470

 

About Feedback plc

 

Feedback plc liberates the data and knowledge from multiple healthcare IT systems and delivers better workflow to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. We connect care settings with diagnostic and other relevant data to drive better, faster, safer decision that improve outcomes for patients.

 

By linking different clinical systems together into a seamless view of the patient, we can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers.

 

Bleepa® is our communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multi-disciplinary team working and diagnostic-enhanced advice and guidance. CareLocker® is our patient-facing platform that gives patients access and control over their diagnostic and other clinical data.

 

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

https://feedbackmedical.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHPPGPWPUPAGAW